FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897942822> ?p ?o ?g. }

• W2897942822 endingPage "e024427" @default.
• W2897942822 startingPage "e024427" @default.
• W2897942822 abstract "Introduction Immune thrombocytopenia (ITP) is an autoimmune condition that may cause thrombocytopenia-related bleeding. Current first-line ITP treatment is with high-dose corticosteroids but frequent side effects, heterogeneous responses and high relapse rates are significant problems with only 20% remaining in sustained remission with this approach. Mycophenolate mofetil (MMF) is often used as the next treatment with efficacy in 50%–80% of patients and good tolerability but can take up to 2 months to work. Objective To test the hypothesis that MMF combined with corticosteroid is a more effective first-line treatment for immune thrombocytopenia (ITP) than current standard of corticosteroid alone. Methods and analysis Design Multicentre, UK-based, open-label, randomised controlled trial. Setting Haematology departments in secondary care. Participants We plan to recruit 120 patients >16 years old with a diagnosis of ITP and a platelet count <30x10 9 /L who require first-line treatment. Patients will be followed up for a minimum of 12 months following randomisation. Primary outcome Time from randomisation to treatment failure defined as platelets <30x10 9 /L and a need for second-line treatment. Secondary outcomes Side effects, bleeding events, remission rates, time to relapse, time to next therapy, cumulative corticosteroid dose, rescue therapy, splenectomy, socioeconomic costs, patient-reported outcomes (quality of life, fatigue, impact of bleeding, care costs). Analysis The sample size of 120 achieves a 91.5% power to detect a doubling of the median time to treatment failure from 5 to 10 months. This will be expressed as an HR with 95% CI, median time to event if more than 50% have had an event and illustrated with Kaplan-Meier curves. Cost-effectiveness will be based on the first 12 months from diagnosis. Ethics and dissemination Ethical approval from NRES Committee South West (IRAS number 225959). EudraCT Number: 2017-001171-23. Results will be submitted for publication in peer-reviewed journals. Trial registration number NCT03156452" @default.
• W2897942822 created "2018-10-26" @default.
• W2897942822 creator A5006455831 @default.
• W2897942822 creator A5008779503 @default.
• W2897942822 creator A5009831126 @default.
• W2897942822 creator A5013438524 @default.
• W2897942822 creator A5025294145 @default.
• W2897942822 creator A5029898835 @default.
• W2897942822 creator A5037675863 @default.
• W2897942822 creator A5072785911 @default.
• W2897942822 creator A5080444722 @default.
• W2897942822 creator A5080752448 @default.
• W2897942822 creator A5086465480 @default.
• W2897942822 creator A5086810447 @default.
• W2897942822 date "2018-10-01" @default.
• W2897942822 modified "2023-10-10" @default.
• W2897942822 title "Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial" @default.
• W2897942822 cites W1968909135 @default.
• W2897942822 cites W1976472818 @default.
• W2897942822 cites W1977622421 @default.
• W2897942822 cites W1984073642 @default.
• W2897942822 cites W1991437102 @default.
• W2897942822 cites W1999095358 @default.
• W2897942822 cites W2016937058 @default.
• W2897942822 cites W2018348575 @default.
• W2897942822 cites W2021515959 @default.
• W2897942822 cites W2036896329 @default.
• W2897942822 cites W2059190713 @default.
• W2897942822 cites W2060637804 @default.
• W2897942822 cites W2063950330 @default.
• W2897942822 cites W2069871327 @default.
• W2897942822 cites W2074887437 @default.
• W2897942822 cites W2077708897 @default.
• W2897942822 cites W2079785691 @default.
• W2897942822 cites W2087692232 @default.
• W2897942822 cites W2105183923 @default.
• W2897942822 cites W2122735473 @default.
• W2897942822 cites W2147981786 @default.
• W2897942822 cites W2165983936 @default.
• W2897942822 cites W2170418307 @default.
• W2897942822 cites W2476679827 @default.
• W2897942822 cites W4243970543 @default.
• W2897942822 doi "https://doi.org/10.1136/bmjopen-2018-024427" @default.
• W2897942822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6196935" @default.
• W2897942822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30341143" @default.
• W2897942822 hasPublicationYear "2018" @default.
• W2897942822 type Work @default.
• W2897942822 sameAs 2897942822 @default.
• W2897942822 citedByCount "16" @default.
• W2897942822 countsByYear W28979428222019 @default.
• W2897942822 countsByYear W28979428222020 @default.
• W2897942822 countsByYear W28979428222021 @default.
• W2897942822 countsByYear W28979428222023 @default.
• W2897942822 crossrefType "journal-article" @default.
• W2897942822 hasAuthorship W2897942822A5006455831 @default.
• W2897942822 hasAuthorship W2897942822A5008779503 @default.
• W2897942822 hasAuthorship W2897942822A5009831126 @default.
• W2897942822 hasAuthorship W2897942822A5013438524 @default.
• W2897942822 hasAuthorship W2897942822A5025294145 @default.
• W2897942822 hasAuthorship W2897942822A5029898835 @default.
• W2897942822 hasAuthorship W2897942822A5037675863 @default.
• W2897942822 hasAuthorship W2897942822A5072785911 @default.
• W2897942822 hasAuthorship W2897942822A5080444722 @default.
• W2897942822 hasAuthorship W2897942822A5080752448 @default.
• W2897942822 hasAuthorship W2897942822A5086465480 @default.
• W2897942822 hasAuthorship W2897942822A5086810447 @default.
• W2897942822 hasBestOaLocation W28979428221 @default.
• W2897942822 hasConcept C109159458 @default.
• W2897942822 hasConcept C126322002 @default.
• W2897942822 hasConcept C141071460 @default.
• W2897942822 hasConcept C168563851 @default.
• W2897942822 hasConcept C187212893 @default.
• W2897942822 hasConcept C197934379 @default.
• W2897942822 hasConcept C202953159 @default.
• W2897942822 hasConcept C203092338 @default.
• W2897942822 hasConcept C2776760755 @default.
• W2897942822 hasConcept C2776804153 @default.
• W2897942822 hasConcept C2776915898 @default.
• W2897942822 hasConcept C2777863708 @default.
• W2897942822 hasConcept C2778375690 @default.
• W2897942822 hasConcept C2779134260 @default.
• W2897942822 hasConcept C2779338263 @default.
• W2897942822 hasConcept C2780653079 @default.
• W2897942822 hasConcept C28328180 @default.
• W2897942822 hasConcept C2993327898 @default.
• W2897942822 hasConcept C54355233 @default.
• W2897942822 hasConcept C71924100 @default.
• W2897942822 hasConcept C86803240 @default.
• W2897942822 hasConcept C89560881 @default.
• W2897942822 hasConceptScore W2897942822C109159458 @default.
• W2897942822 hasConceptScore W2897942822C126322002 @default.
• W2897942822 hasConceptScore W2897942822C141071460 @default.
• W2897942822 hasConceptScore W2897942822C168563851 @default.
• W2897942822 hasConceptScore W2897942822C187212893 @default.
• W2897942822 hasConceptScore W2897942822C197934379 @default.
• W2897942822 hasConceptScore W2897942822C202953159 @default.
• W2897942822 hasConceptScore W2897942822C203092338 @default.
• W2897942822 hasConceptScore W2897942822C2776760755 @default.

• next